Valneva Stock
Valneva SE
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- France
- CEO
- Thomas Lingelbach
- Employees
- 674
- Market cap
- $509 M
- IPO
- 05/05/2021
- Web
- valneva.com
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from…
Valneva stock: price history
1D
-5.1%
1W
-2.9%
1M
-14.6%
6M
-5.9%
YTD
-36.4%
1Y
-45.2%
2Y
+0.2%
5Y
-80.0%
10Y
–
Next earnings date
Next earnings date
19/11/2026 (in 33 days)
Volatility around earnings
~11% weaker price swings than usual
Ask the agents about Valneva
Analyst assessment of Valneva
PRICE TARGET LOW
US$11.00
CONSENSUS
US$17.00
MEDIAN
US$14.00
PRICE TARGET HIGH
US$26.00
0
STRONG BUY
2
BUY
0
HOLD
1
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 22/04/2026
Valneva stock metrics
P/E
-2.8
P/B
5.89
EV/EBITDA
-5.5
RETURN ON EQUITY
-39.1%
NET MARGIN
-89.3%
DEBT/EQUITY
2.59
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
96.8%
FLOAT SHARES
87,857,066
AVG. DAILY VOLUME (30D)
24,084
Institutional holders
Comparable stocks
Frequently asked questions about Valneva stock
What does Valneva do?
Valneva SE is a company in the Healthcare sector, Biotechnology industry, headquartered in France.
The CEO is Thomas Lingelbach, the company employs around 674 people.
The IPO was on 05/05/2021; the stock trades on NASDAQ under the ticker VALN.
What do analysts say about Valneva stock?
3 analysts rate the stock, the consensus is Buy (as of 22/04/2026).
The average price target is US$17.00, ranging from US$11.00 to US$26.00, with a median of US$14.00.
This is an external assessment, not a statement by Market Jury.
When does Valneva report next?
The next earnings date is 19/11/2026.
Around past earnings, price swings were roughly -11% stronger than usual.
Does Valneva pay a dividend?
No, Valneva currently does not pay a dividend.
Which stocks are comparable to Valneva?
Comparable stocks include Nanobiotix, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Valneva stock analyzed?
Clicking "Analyze stock" lets five strategies assess Valneva against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.